|Bid||184.47 x 200|
|Ask||184.54 x 400|
|Day's Range||184.17 - 187.45|
|52 Week Range||150.38 - 191.10|
|PE Ratio (TTM)||16.68|
|Forward Dividend & Yield||5.28 (2.85%)|
|1y Target Est||N/A|
Stocks marched to new highs Tuesday as Merck, Apple and Microsoft boosted the Dow. But Bitcoin dived.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.
Announcement: Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law. Global Credit Research- 09 Jan 2018. New York, January 09, 2018-- US pharmaceutical companies' cash holdings ...
Few would call the biotech sector as exciting as the "FAANG" group. But throughout 2017, investors who completely ignored biotech stocks missed out on strong gains. The Nasdaq Biotechnology ...
AbbVie’s (ABBV) market-leading immunology drug, Humira (adalimumab), reported worldwide revenues of $4.7 billion in 3Q17.
Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma. Xgeva has already been approved to treat a condition ...